EMAIL THIS PAGE TO A FRIEND

Hospital medicine (London, England : 1998)

Leuprorelin: a leading role in advanced prostate cancer therapy.


PMID 12833832

Abstract

Leuprorelin is a luteinizing hormone-releasing hormone analogue, licensed in the UK for the treatment of advanced prostate cancer. This review highlights the efficacy and tolerance of this agent and the benefits provided for developing patient-centred therapy and optimizing patient quality of life.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

L0376000 Leuprorelin, European Pharmacopoeia (EP) Reference Standard
C59H84N16O12